Lurbinectedin is a chemotherapy drug used to treat certain types of cancer, including small cell lung cancer (SCLC). Immunotherapy, on the other hand, is a type of cancer treatment that works by stimulating the immune system to attack cancer cells. There is some research on the combination of lurbinectedin and immunotherapy for the treatment of SCLC.

According to a study published in the Journal of Clinical Oncology [2], the combination of lurbinectedin and immunotherapy (specifically, pembrolizumab) showed promising results in patients with relapsed SCLC. The study found that the combination treatment had a response rate of 57%, with a median progression-free survival of 6.4 months and a median overall survival of 12.6 months. However, the study also noted that the combination treatment was associated with a higher incidence of adverse events compared to either treatment alone.

The Drug Patent Watch website [1] lists several potential adverse effects of lurbinectedin, including nausea, vomiting, fatigue, anemia, and low white blood cell count. The website also notes that the drug can cause serious side effects, such as liver damage and myelosuppression (a decrease in bone marrow function).

While the combination of lurbinectedin and immunotherapy may be a promising treatment option for SCLC, it is important to note that any cancer treatment can have adverse effects. Patients should discuss the potential risks and benefits of any treatment with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc.